Boston Scientific ( BSX +0.8% ) receives CE Mark clearance for its Vercise Deep Brain Stimulation (DBS) System for the treatment of tremor, including
Alcatel-Lucent, S.A. (NYSE: ALU ), Dollar Tree (NASDAQ: DLTR ), Caterpillar (NYSE: CAT ) and Boston Scientific (NYSE: BSX ) (2 purchases). The second portfolio consists of Universal Insurance Holdings (NYSE: UVE ), Gray Television
Sept 9 (Reuters) - A Texas jury has ordered Boston Scientific Corp to pay $73 million to a woman who said she suffered serious injuries from a transvaginal mesh device, the first loss for the device maker in one of thousands of suits over the products.
BARCELONA, Sept 1 (Reuters) - A nerve stimulation device from Cyberonics improved cardiac function in heart failure patients in a small clinical trial, in contrast to an unsuccessful study backed by Boston Scientific .
BARCELONA, Aug 30 (Reuters) - A Boston Scientific device that stimulates the vagus nerve - a superhighway connecting the brain to the rest of the body - failed to help patients with heart failure in a mid-stage clinical trial.
device companies such as Medtronic, St. Jude and Boston Scientific . During the next five years, we expect key demographic ..... device companies such as Medtronic , St. Jude, and Boston Scientific . During the next five years, we expect key demographic
had cautiously anticipated rising competition now that Medtronic has entered the U.S. and St. Jude Medical and Boston Scientific have launched in Europe, Edwards showed its own strength in both markets with its rollout of Sapien XT and Sapien
25% of claims so far.With growth in the cardiac device markets slowing, deep-pocketed competitors, such as Boston Scientific , Abbott, and Johnson & Johnson, could encroach on Bard's vascular and surgical specialties markets.The low
Boston Scientific released second-quarter performance that exceeded our expectations, and we plan to modestly increase our fair value estimate
Additionally, it is not yet clear what magnitude of exposure Stryker faces for damages related to the implants.Thanks to Boston Scientific 's historical underinvestment in its neurovascular segment, Stryker must now play catch up in order to maintain